Novartis gets EU approval for Cushing's drug

ZURICH, April 25 Wed Apr 25, 2012 1:24am EDT

Related Topics

ZURICH, April 25 (Reuters) - Swiss drugmaker Novartis AG (NOVN.VX) said on Wednesday it has won European Union approval for its Signifor as the first medical therapy for Cushing's disease, a rare hormonal disorder.

Signifor, which is designed for Cushing's disease patients who cannot have surgery or for whom surgery has not been successful, had already won a green light from the European Medicines Agency (EMA) in January. [ID:nL6E8CK24E]

Cushing's is caused by a small tumour of the pituitary gland making too much of a hormone. Standard treatment is surgical removal of the tumour, but this does not always work.

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.